Ayala Pharmaceuticals (ADXS) Competitors $0.03 +0.00 (+3.00%) As of 02:23 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. CLDI, KTTA, AEZS, TTNP, BCTX, ADTX, PBM, PALI, TCRT, and SPRBShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Calidi Biotherapeutics (CLDI), Pasithea Therapeutics (KTTA), Aeterna Zentaris (AEZS), Titan Pharmaceuticals (TTNP), Briacell Therap (BCTX), Aditxt (ADTX), Psyence Biomedical (PBM), Palisade Bio (PALI), Alaunos Therapeutics (TCRT), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Its Competitors Calidi Biotherapeutics Pasithea Therapeutics Aeterna Zentaris Titan Pharmaceuticals Briacell Therap Aditxt Psyence Biomedical Palisade Bio Alaunos Therapeutics Spruce Biosciences Calidi Biotherapeutics (NYSE:CLDI) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Is CLDI or ADXS more profitable? Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Ayala Pharmaceuticals N/A N/A N/A Does the media refer more to CLDI or ADXS? In the previous week, Calidi Biotherapeutics had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for Calidi Biotherapeutics and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Calidi Biotherapeutics' score of -1.00 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Calidi Biotherapeutics Negative Ayala Pharmaceuticals Neutral Which has preferable valuation & earnings, CLDI or ADXS? Calidi Biotherapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi BiotherapeuticsN/AN/A-$29.22MN/AN/AAyala Pharmaceuticals$3.24M0.45-$48.07M-$7.980.00 Which has more risk and volatility, CLDI or ADXS? Calidi Biotherapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Do institutionals & insiders believe in CLDI or ADXS? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryCalidi Biotherapeutics and Ayala Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46M$852.53M$5.69B$10.27BDividend YieldN/A4.84%5.72%4.60%P/E Ratio0.001.1975.8626.51Price / Sales0.4526.62489.92165.26Price / CashN/A19.5625.8129.89Price / Book-0.026.6612.846.32Net Income-$48.07M-$4.13M$3.28B$270.51M7 Day PerformanceN/A2.39%0.22%2.15%1 Month PerformanceN/A7.86%4.61%6.35%1 Year PerformanceN/A23.73%68.33%25.48% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03+3.0%N/A+66.5%$1.46M$3.24M0.0020Gap UpCLDICalidi Biotherapeutics0.3505 of 5 stars$1.65flatN/A-88.5%$5.65MN/A0.0038Short Interest ↑KTTAPasithea Therapeutics0.6118 of 5 stars$0.76-1.4%N/A-80.1%$5.65MN/A-0.103News CoveragePositive NewsAEZSAeterna ZentarisN/A$3.08+1.3%N/A-26.0%$5.52M$2.37M-0.2120TTNPTitan Pharmaceuticals0.1403 of 5 stars$4.13+1.1%N/A-19.9%$5.49MN/A-1.4010Positive NewsShort Interest ↑Gap DownBCTXBriacell Therap2.8515 of 5 stars$7.97-0.3%$320.00+3,915.1%-90.4%$5.42MN/A-0.108News CoverageShort Interest ↓ADTXAditxtN/A$1.07+16.1%N/A-100.0%$5.33M$130K0.0060News CoveragePBMPsyence Biomedical0.6822 of 5 stars$2.82-1.4%N/A-95.9%$5.27MN/A0.00N/APALIPalisade Bio3.3502 of 5 stars$0.56-1.9%$12.00+2,042.9%-84.4%$5.11M$250K-0.1410Short Interest ↓Gap DownTCRTAlaunos Therapeutics0.3353 of 5 stars$2.30+5.0%N/A-3.4%$5.08M$10K-0.9340Positive NewsGap UpSPRBSpruce Biosciences1.1087 of 5 stars$9.00flat$131.25+1,358.3%-71.9%$5.06M$4.91M-9.5720News Coverage Related Companies and Tools Related Companies Calidi Biotherapeutics Alternatives Pasithea Therapeutics Alternatives Aeterna Zentaris Alternatives Titan Pharmaceuticals Alternatives Briacell Therap Alternatives Aditxt Alternatives Psyence Biomedical Alternatives Palisade Bio Alternatives Alaunos Therapeutics Alternatives Spruce Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
